Clavis does an ENT around

Clavis Pharma ASA hopes its elacytarabine can provide greater efficacy than other nucleoside analogs used to treat cancer because it doesn't rely on a cellular transporter to get into the tumor cell. New Phase II data in acute myelogenous leukemia support the hypothesis.

In AML, standard first-line therapy is generic cytarabine plus an anthracycline. According to CMO Athos Gianella-Borradori, nucleoside analogs used to treat cancer, such as cytarabine and Gemzar gemcitabine, depend on ENT1 for entry into cancer cells...